顺势疗法的预后因素研究:方法概述,与条件受限研究的见解
Anjali Miglani1, Raj Kumar Manchanda2, Lex Rutten3
1Directorate of AYUSH, Health and Family Welfare Department, Government of National Capital Territory of Delhi, New Delhi, India.
顺势疗法中的预后因素研究 (PFR),特别是条件限制的PFR (CC-PFR),确定了选择药物的关键症状. 在COVID-19期间的CC-PFR研究表明了可重现性和通用性,有助于治疗决策.
科学领域:
- 顺势疗法的研究方法学.
- 临床流行病学临床流行病学
- 基于证据的医学是基于证据的医学.
背景情况:
- 预后因素 (PF) 预测疾病的结果.
- 预后因素研究 (PFR) 正在在顺势疗法中出现,用于治疗决策.
- 条件限制PFR (CC-PFR) 将研究缩小到特定的患者亚群.
研究的目的:
- 概述在顺势疗法中的预后因素研究 (PFR).
- 总结COVID-19中条件受限PFR (CC-PFR) 研究的发现.
- 概述CC-PFR研究中的方法,挑战和经验教训.
主要方法:
- 一个PFR文献的审查.
- 在COVID-19大流行期间进行的六项CC-PFR研究的摘要.
- 分析方法,挑战,结果解释和经验教训.
主要成果:
- 六项CC-PFR研究确定了COVID-19期间10种经常使用的顺势疗法药物的预后因素.
- 预后因素,通常是常见的症状,在结合时变得特定,有助于药物差异化.
- CC-PFR模型证明了可重复性,可验证性,可通用性,并导致了迷你目录和应用程序.
结论:
- CC-PFR增强了对常见症状的可靠使用,减少了对特殊症状和确认偏差的依赖.
- 对于具有罕见/特殊症状或流行病的疾病,CC-PFR是有价值的.
- 可靠的观察是至关重要的;培训从业人员收集数据,偏见管理和因果分析是必不可少的.
更多相关视频
07:32Author Spotlight: Investigating Immune Cell Dynamics in the Tumor Microenvironment — Challenges and Innovations in Cancer Prognosis
Published on: April 12, 2024
06:46Competing-Risk Nomogram for Predicting Cancer-Specific Survival in Multiple Primary Colorectal Cancer Patients after Surgery
Published on: September 27, 2024
相关概念视频
Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches
Non-controlled studies, commonly employed for initial exploration, lack a control group, rendering them susceptible to biases and external influences. In contrast,...
Cancer Survival Analysis
Comparing the Survival Analysis of Two or More Groups
Factors Affecting Illness
For instance, risk factors are connected to illness,...
Combination Therapies and Personalized Medicine
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
Factors Influencing Drug Absorption: Disease States and Pharmacology
Substances such as alcohol and specific drugs, including antineoplastics, can also negatively impact drug absorption. For instance,...
